TRIVASTAL RETARD Prolonged-release Tablet

Piribedil
50 mg
Alfasigma S.p.A
Pack size 1 Blister (30 Tablets)
Dispensing mode
Source
Agent
Retail Price 1.05 AED

Indications

TRIVASTAL RETARD Prolonged-release Tablet is used for: ? Treatment of Parkinson's disease (PD), either as monotherapy (without levodopa)) or in combination with L-DOPA therapy, in the early stages of the disease as well as in the advanced ones
? Treatment of pathological cognitive deficits in the elderly (impaired attention, motivation, memory, etc.)
? Treatment of dizziness in the elderly
? Treatment of retinal ischemic manifestations
? Adjunctive treatment of intermittent claudication due to peripheral vascular disease (PVD) of the lower limbs (stage 2)
? Adjunctive treatment of anhedonia and treatment-resistant depression in unipolar and bipolar depressives (off label)
? Treatment of gait disorders associated with Parkinson's disease (no related cause) and other forms of parkinsonism

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Piribedil :

Mechanism of Action

Note

TRIVASTAL RETARD 50 mg Prolonged-release Tablet manufactured by Alfasigma S.p.A. Its generic name is Piribedil. TRIVASTAL RETARD is availble in Saudi Arabia. Farmaco SA drug index information on TRIVASTAL RETARD Prolonged-release Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Piribedil :